Repeated oral rifampicin decreases the jejunal permeability of R/S- verapamil in rats

Drug Metabolism and Disposition

Volumn 27, Issue 8, 1999, Pages 951-955

  Sandström, Rikard ^a   Lennernäs, Hans ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME; GLUCOSE; NORVERAPAMIL; RIFAMPICIN; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG PENETRATION; ENANTIOMER; INTESTINE CELL; JEJUNUM; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY;

ALGORITHMS; ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; CALCIUM CHANNEL BLOCKERS; GLUCOSE; INTESTINAL ABSORPTION; JEJUNUM; MALE; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; RIFAMPIN; STEREOISOMERISM; VERAPAMIL;

EID: 0032770435     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Benet LZ, Wu CY, Hebert MF and Wacher VJ (1996). Intestinal drug metabolism and anti-transport processes: A potential paradigm shift in oral drug delivery. J Control Release 39:139-143.
2. Calleja C, Pascussi JM, Mani JC, Maurel P and Vilarem MJ (1998) The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor [see comments]. Nat Med 4:92-96.
3. Fagerholm U, Johansson M and Lennernäs H (1996) Comparison between permeability coefficients in rat and human jejunum. Pharm Res 13:1336-1342.
4. Fromm MF, Busse D, Kroemer HK and Eichelbaum M (1996) Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796-801.
5. Haussermann K, Benz B, Gekeler V, Schumacher K and Eichelbaum M (1991) Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines. Eur J Clin Pharmacol 40:53-59.
6. Kolars JC, Schmiedlin RP, Dobbins WD, Schuetz J, Wrighton SA and Watkins PB (1992) Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102:1186-1198.
7. Kroemer HK, Echizen H, Heidemann H and Eichelbaum M (1992) Predictability of the in vivo metabolism of verapamil from in vitro data: Contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Ther 260:1052-1057.
8. Lennernäs H, Ahrenstedt O, Hallgren R, Knutson L, Ryde M and Paalzow LK (1992) Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm Res 9:1243-1251.
9. Levitt MD, Kneip JM and Levitt DG (1988) Use of laminar flow and unstirred layer models to predict intestinal absorption in the rat. J Clin Invest 81:1365-1369.
10. Lown KS, Kolars JC, Ghosh M, Schmiedlin-Ren P and Watkins PB (1996) Induction of MDR1 expression in normal rat and human intestine in vivo. Gastroenterology 110:344.
11. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin RP, Brown MB, Guo W, Rossi SJ, Benet LZ and Watkins PB (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260.
12. Oesch F, Arand M, Benedetti MS, Castelli MG and Dostert P (1996) Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J Antimicrob Chemother 37:1111-1119.
13. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
14. Regardh CG, Edgar B, Olsson R, Kendall M, Collste P and Shansky C (1989) Pharmacokinetics of felodipine in patients with liver disease. Eur J Clin Pharmacol 36:473-479.
15. Saitoh H and Aungst BJ (1995) Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm Res 12:1304-1310.
16. Salphati L and Benet LZ (1998) Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol 55:387-395.
17. Sandstrom R, Karlsson A, Knutson L and Lennernas H (1998a) Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm Res 15:856-862.
18. Sandstrom R, Karlsson A and Lennernäs H (1998b) The absence of stereoselective P-glycoprotein mediated transport of R/S-verapamil across the rat jejunum. J Pharm Pharmacol 50:729-735.
19. Sandstrom R, Lennernäs H, Öhlén K and Karlsson A (1999) Enantiomeric separation of verapamil and norverapamil using chiral-AGP as the stationary phase. J Pharm Biomed Anal. in press.
20. Schuetz EG, Beck WT and Schuetz JD (1996a) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
21. Schuetz EG, Schinkel AH, Relling MV and Schuetz JD (1996b) P-Glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001-4005.
22. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
23. Wacher VJ, Wu CY and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
24. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036.
25. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY and Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 58:492-497.
26. Zilly W, Breimer DD and Richter E (1975) Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol 9:219-227.
27. Zilly W, Breimer DD and Richter E (1977a) Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet 2:61-70.
28. Zilly W, Breimer DD and Richter E (1977b) Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol 11:287-293.